440
90. Li X, Shang H, Wu W, Li S, Lin Z, Duan J, et al. Glucose-responsive micelles for controlled
insulin release based on transformation from amphiphilic to double hydrophilic. J Nanosci
Nanotechnol. 2016;16(6):5457–63.
91. Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of
insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules. 2013;15(1):350–60.
92. Haslam D, James W. Obesity. Lancet. 2005;366(9492):1.
93. Ceriello A. Diabete e Cancro. Cancer Epidemiol Biomark Prev. 2005;14:138–47.
94. Chen H, Dorrigan A, Saad S, Hare DJ, Cortie MB, Valenzuela SM. In vivo study of
spherical gold nanoparticles: inflammatory effects and distribution in mice. PLoS One.
2013;8(2):e58208.. Epub 2013/02/28. eng
95. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-dependent cytotoxicity of
gold nanoparticles. Small. 2007;3(11):1941–9.
96. Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities
for hypertension. Drug Deliv. 2017;24(1):358–69.
97. Thomas TP, Goonewardena SN, Majoros IJ, Kotlyar A, Cao Z, Leroueil PR, et al. Folatetargeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis
Rheum. 2011;63(9):2671–80.
98. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles:
an overview of biomedical applications. J Control Release. 2012;161(2):505–22.
99. Sethi V, Önyüksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods
Enzymol. 2005;391:377–95.
100. Deshpande PB, Gurram AK, Deshpande A, Shavi GV, Musmade P, Arumugam K, et al. A
novel nanoproliposomes of lercanidipine: development, in vitro and preclinical studies to
support its effectiveness in hypertension therapy. Life Sci. 2016;162:125–37.
101. JIA H. CHANG C-y. establishment of the method for determination of copper and zinc in
PC-SOD∗. Chinese J Pharmaceut Anal. 2016;36(5):821–5.
102. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery
systems. Pharmacol. Rep. 2012;64(5):1020–37.
103. Giacalone G, Tsapis N, Mousnier L, Chacun H, Fattal E. PLA-PEG nanoparticles improve
the anti-inflammatory effect of rosiglitazone on macrophages by enhancing drug uptake compared to free rosiglitazone. Materials. 2018;11(10):1845.
104. Santana R, Perrechil F, Cunha R. High-and low-energy emulsifications for food applications:
a focus on process parameters. Food Eng Rev. 2013;5(2):107–22.
105. Anderson CD, Daniels ES. Emulsion Polymerisation and Latex Applications. Shrewsbury:
ISmithers Rapra Publishing; 2003.
106. Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma M. Nano-emulsions. Curr Opin
Colloid Interface Sci. 2005;10(3):102–10.
107. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev.
2002;54:S77–98.
108. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a
novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238–57.
109. Sisson AL, Papp I, Landfester K, Haag R. Functional nanoparticles from dendritic precursors: hierarchical assembly in miniemulsion. Macromolecules. 2008;42(2):556–9.
110. Chaudhary H, Kumar V. Taguchi design for optimization and development of antibacterial
drug-loaded PLGA nanoparticles. Int J Biol Macromol. 2014;64:99–105.
111. Shah U, Joshi G, Sawant K. Improvement in antihypertensive and antianginal effects of
felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design.
Mater Sci Eng C. 2014;35:153–63.
112. Tsai Y-M, Chien C-F, Lin L-C, Tsai T-H. Curcumin and its nano-formulation: the kinetics of
tissue distribution and blood–brain barrier penetration. Int J Pharm. 2011;416(1):331–8.
Z. Iqbal et al.
90. Li X, Shang H, Wu W, Li S, Lin Z, Duan J, et al. Glucose-responsive micelles for controlled
insulin release based on transformation from amphiphilic to double hydrophilic. J Nanosci
Nanotechnol. 2016;16(6):5457–63.
91. Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of
insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules. 2013;15(1):350–60.
92. Haslam D, James W. Obesity. Lancet. 2005;366(9492):1.
93. Ceriello A. Diabete e Cancro. Cancer Epidemiol Biomark Prev. 2005;14:138–47.
94. Chen H, Dorrigan A, Saad S, Hare DJ, Cortie MB, Valenzuela SM. In vivo study of
spherical gold nanoparticles: inflammatory effects and distribution in mice. PLoS One.
2013;8(2):e58208.. Epub 2013/02/28. eng
95. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-dependent cytotoxicity of
gold nanoparticles. Small. 2007;3(11):1941–9.
96. Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities
for hypertension. Drug Deliv. 2017;24(1):358–69.
97. Thomas TP, Goonewardena SN, Majoros IJ, Kotlyar A, Cao Z, Leroueil PR, et al. Folatetargeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis
Rheum. 2011;63(9):2671–80.
98. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles:
an overview of biomedical applications. J Control Release. 2012;161(2):505–22.
99. Sethi V, Önyüksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods
Enzymol. 2005;391:377–95.
100. Deshpande PB, Gurram AK, Deshpande A, Shavi GV, Musmade P, Arumugam K, et al. A
novel nanoproliposomes of lercanidipine: development, in vitro and preclinical studies to
support its effectiveness in hypertension therapy. Life Sci. 2016;162:125–37.
101. JIA H. CHANG C-y. establishment of the method for determination of copper and zinc in
PC-SOD∗. Chinese J Pharmaceut Anal. 2016;36(5):821–5.
102. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery
systems. Pharmacol. Rep. 2012;64(5):1020–37.
103. Giacalone G, Tsapis N, Mousnier L, Chacun H, Fattal E. PLA-PEG nanoparticles improve
the anti-inflammatory effect of rosiglitazone on macrophages by enhancing drug uptake compared to free rosiglitazone. Materials. 2018;11(10):1845.
104. Santana R, Perrechil F, Cunha R. High-and low-energy emulsifications for food applications:
a focus on process parameters. Food Eng Rev. 2013;5(2):107–22.
105. Anderson CD, Daniels ES. Emulsion Polymerisation and Latex Applications. Shrewsbury:
ISmithers Rapra Publishing; 2003.
106. Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma M. Nano-emulsions. Curr Opin
Colloid Interface Sci. 2005;10(3):102–10.
107. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev.
2002;54:S77–98.
108. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a
novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238–57.
109. Sisson AL, Papp I, Landfester K, Haag R. Functional nanoparticles from dendritic precursors: hierarchical assembly in miniemulsion. Macromolecules. 2008;42(2):556–9.
110. Chaudhary H, Kumar V. Taguchi design for optimization and development of antibacterial
drug-loaded PLGA nanoparticles. Int J Biol Macromol. 2014;64:99–105.
111. Shah U, Joshi G, Sawant K. Improvement in antihypertensive and antianginal effects of
felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design.
Mater Sci Eng C. 2014;35:153–63.
112. Tsai Y-M, Chien C-F, Lin L-C, Tsai T-H. Curcumin and its nano-formulation: the kinetics of
tissue distribution and blood–brain barrier penetration. Int J Pharm. 2011;416(1):331–8.
Z. Iqbal et al.